Substance P Induction of Itch-associated Response Mediated by Cutaneous NK1 Tachykinin Receptors in Mice
Overview
Authors
Affiliations
Our experiments were conducted to determine whether substance P (SP) would elicit an itch sensation mediated by mast cells in mice. An intradermal injection of SP (10-135 microgram site-1) into the rostral back of the ICR mouse dose-dependently produced scratching of the injected site. The SP- (135 microgram site-1 = 100 nmol site-1) induced scratching was inhibited by capsaicin (repeated administration) and naloxone; features being similar to itch in humans. SP elicited scratching in mast cell-deficient (WBB6F1 W/Wv) mice as well as control (+/+) mice. Pretreatment with compound 48/80 produced similar degrees of inhibition of SP-induced scratching in mast cell-deficient mice as well as control +/+ and ICR mice. Intradermal injections of the NK1 receptor agonist GR73632 produced dose-dependent scratching, while the NK2 agonist GR64349 and the NK3 agonist senktide were without effects. SP-induced scratching was inhibited by the NK1 receptor antagonists spantide and L-668,169, but not by the NK2 antagonist L-659,877. The results suggest that scratching of the mouse induced by an i.d. injection of SP is itch-associated response. The SP action may be mediated at least partly by cutaneous NK1 receptors, and mast cells may not be key factors in SP-induced itching.
Seemab K, Khan A, Khan M, Qazi N, Minhas A, Ali F BMC Pharmacol Toxicol. 2024; 25(1):32.
PMID: 38778384 PMC: 11110330. DOI: 10.1186/s40360-024-00748-4.
Molecular mechanisms of pruritus in prurigo nodularis.
Shao Y, Wang D, Zhu Y, Xiao Z, Jin T, Peng L Front Immunol. 2023; 14:1301817.
PMID: 38077377 PMC: 10701428. DOI: 10.3389/fimmu.2023.1301817.
Pathogenesis and Treatment of Pruritus Associated with Chronic Kidney Disease and Cholestasis.
Kim J, Shim W, Kwak I, Lee D, Park J, Lee S Int J Mol Sci. 2023; 24(2).
PMID: 36675074 PMC: 9864517. DOI: 10.3390/ijms24021559.
Critical Players and Therapeutic Targets in Chronic Itch.
Yang H, Chen W, Zhu R, Wang J, Meng J Int J Mol Sci. 2022; 23(17).
PMID: 36077340 PMC: 9456029. DOI: 10.3390/ijms23179935.
Nguyen L, Choi M, Shin H, Yang I Evid Based Complement Alternat Med. 2022; 2022:1307173.
PMID: 35368752 PMC: 8967505. DOI: 10.1155/2022/1307173.